Why the ‘Scope of the Patent’ Test Cannot Solve the Drug Patent Settlement Problem
Why the ‘Scope of the Patent’ Test Cannot Solve the Drug Patent Settlement Problem by Michael A. Carrier, Rutgers University School of Law – Camden
ABSTRACT: One of the most difficult legal issues today involves settlements by which brand-name drug companies pay generic firms to delay entering the market. Such conduct requires courts to consider not only patent and antitrust law, but also the Hatch-Waxman Act, the complex regime governing behavior in the pharmaceutical industry. Courts have analyzed these agreements by relying on a test that asks if the settlement falls within the “scope of the patent.” They have found, in nearly all of these cases, that it does. And, as a result, they have concluded that the agreements do not violate the antitrust laws. This 8-page article shows why the scope test is not appropriate in determining the antitrust treatment of drug patent settlements. It recounts the history of the test, showing its increasing deference over time. And it demonstrates the three primary problems with the test: (1) it involves a transformation that has left the test toothless, (2) it assumes that the patent at issue is valid, and (3) it neglects the issue of infringement.”
Featured News
Senator Warner Calls for Treasury Oversight on Big Tech Sanctions
Jan 29, 2024 by
CPI
Canada’s Industry Minister Targets Grocery Giants with Antitrust Changes
Jan 29, 2024 by
CPI
DOT Issues Provisional Ruling Ending Delta-Aeroméxico Partnership
Jan 29, 2024 by
CPI
US Targets China with Proposed Rules on Cloud Giants in AI Development
Jan 29, 2024 by
CPI
Australia’s ACCC Finds Limited Evidence of Profiteering in Childcare Sector Despite Soaring Fees
Jan 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI